Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
teprotumumab + tislelizumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination of two separate monoclonal antibodies: **Teprotumumab** is a fully human IgG1 monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) for the treatment of thyroid eye disease (TED). It was approved by the FDA in January 2020 as the first drug for TED. **Tislelizumab** is a humanized IgG4 monoclonal antibody that binds to PD-1 on T cells, preventing cancer cells from suppressing the immune system. It is approved for esophageal squamous cell carcinoma (ESCC) and gastric/gastroesophageal junction adenocarcinoma.
- Brand names
- Tepezza (teprotumumab)Tevimbra (tislelizumab-jsgr)
- Other names
- teprotumumab-trbwtislelizumab-jsgr
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on teprotumumab + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on teprotumumab + tislelizumab.